Pfizer – Ends Immunostimulatory Conjugate Program

Summary Pfizer has discontinued a Phase 1 immunostimulatory drug-conjugate program in oncology, highlighting challenges in developing next-generation targeted delivery modalities. What Happened Pfizer ended development of an early-stage immunostimulatory drug-conjugate candidate that had been in Phase 1 testing. The program aimed to combine targeted delivery…